Arrowhead Pharmaceuticals, Inc.
Financials
Valuation Metrics
Arrowhead Pharmaceuticals, Inc.'s Market Cap is $9.37B. At end of 2025 it was $9.30B. Ranked #956 of 3,121 in US market (top 31%), #310 of 1,463 on NASDAQ (top 21%), #48 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 18%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.37B | US#956/3,121 Sec#48/266 |
| Revenue | $669M | US#2,140/3,121 Sec#69/266 |
| Net Income | $-320M | US—/3,121 Sec—/266 |
| Total Assets | $2.11B | US#2,049/3,121 Sec#57/266 |
| Net Assets | $466M | US#2,279/3,121 Sec#115/266 |
| Employees | 711 | US#2,126/3,121 Sec#69/266 |
| Value | ||
| P/B | 20.13x | US#2,801/3,121 Sec#219/266 |
| P/S | 14.00x | US#2,779/3,121 Sec#128/266 |
| FCF Yield | -0.80% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -68.73% | US#2,749/3,121 Sec#183/266 |
| ROA | -15.15% | US#2,748/3,121 Sec#117/266 |
| Op. Margin | -33.82% | US#2,651/3,121 Sec#106/266 |
| Revenue Growth | 16.85% | US#824/3,121 Sec#80/266 |
| Financial Health | ||
| Debt Ratio | 353.57% | US#2,222/3,121 Sec#219/266 |
| Total Debt | $864M | US#1,616/3,121 Sec#46/266 |
| FCF | $-75M | US#2,585/3,121 Sec#129/266 |
| Cash | $55M | US#2,550/3,121 Sec#222/266 |
| Current Ratio | 5.90x | US#402/3,121 Sec#126/266 |
| Performance | ||
| 1Y Return | 111.11% | US#137/3,121 Sec#49/266 |
| 1M Return | -25.60% | US#3,016/3,121 Sec#249/266 |
| From 52W High | -30.34% | US#2,011/3,121 Sec#158/266 |
| 1Y MDD | -26.57% | US#1,164/3,121 Sec#64/266 |
| Trading | ||
| Volume | 1,768,978 shares | US#563/3,121 Sec#49/266 |
| Trading Value | $118M | US#439/3,121 Sec#25/266 |
| Per Share | ||
| EPS | $-2.27 | US—/3,121 Sec—/266 |
| BPS | $3.31 | US#2,455/3,121 Sec#159/266 |
Company Info
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.